検索
Adagene Inc
ADAGウォッチリストに追加
3.750USD
+0.020+0.54%
終値 07-31 16:00（ET）15分遅れの株価
247.69M時価総額
損失額直近12ヶ月PER
詳細情報 Adagene Inc 企業名
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. The Company is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.
Adagene Incの企業情報
企業コードADAG
会社名Adagene Inc
上場日Feb 09, 2021
最高経営責任者「CEO」Luo (Peter)
従業員数138
証券種類Depository Receipt
決算期末Feb 09
本社所在地4F, Building C14, No. 218, Xinghu Street
都市SUZHOU
証券取引所NASDAQ OMX - NASDAQ BASIC
国China
郵便番号- -
電話番号8651287773632
ウェブサイトhttps://www.adagene.com/
企業コードADAG
上場日Feb 09, 2021
最高経営責任者「CEO」Luo (Peter)
Adagene Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.60M
+11.48%
Ms. She (Kristine) Xiaohong
Ms. She (Kristine) Xiaohong
Senior Vice President, Head of Clinical Operations
Senior Vice President, Head of Clinical Operations
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Wang (Ron) Yuren, Ph.D.
Dr. Wang (Ron) Yuren, Ph.D.
Head of Portfolio Management
Head of Portfolio Management
--
--
Dr. Shang Jin
Dr. Shang Jin
Senior Vice President of Global Regulatory Affairs
Senior Vice President of Global Regulatory Affairs
--
--
Dr. Zheng Songmao
Dr. Zheng Songmao
Associate Vice President of Research and Development
Associate Vice President of Research and Development
--
--
Dr. Zha Jiping, Ph.D.
Dr. Zha Jiping, Ph.D.
Executive Vice President of Clinical Development
Executive Vice President of Clinical Development
--
--
Dr. Zeng Wenlin, Ph.D.
Dr. Zeng Wenlin, Ph.D.
Vice President of Cell Line and Upstream
Vice President of Cell Line and Upstream
--
--
Ms. Ami Knoefler
Ms. Ami Knoefler
Vice President of Investor Relations and Corporate Communications
Vice President of Investor Relations and Corporate Communications
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Peter (Peizhi) Luo, Ph.D.
Dr. Peter (Peizhi) Luo, Ph.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
1.60M
+11.48%
Ms. She (Kristine) Xiaohong
Ms. She (Kristine) Xiaohong
Senior Vice President, Head of Clinical Operations
Senior Vice President, Head of Clinical Operations
--
--
Dr. Liu Guizhong, Ph.D.
Dr. Liu Guizhong, Ph.D.
Head of Biology and Pharmacology
Head of Biology and Pharmacology
--
--
Mr. Alexander Goergen
Mr. Alexander Goergen
Head of Business Development
Head of Business Development
--
--
Dr. Wang (Ron) Yuren, Ph.D.
Dr. Wang (Ron) Yuren, Ph.D.
Head of Portfolio Management
Head of Portfolio Management
--
--
Dr. Shang Jin
Dr. Shang Jin
Senior Vice President of Global Regulatory Affairs
Senior Vice President of Global Regulatory Affairs
--
--
よくある質問
Adagene Incの上位5名の株主は誰ですか？
Adagene Incの上位5名の株主は以下のとおりです。Dr. Peter (Peizhi) Luo, Ph.D.
Adagene Inc（ADAG）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Adagene Incの株式を保有している機関は38社あり、保有株式の総市場価値は約13.55Mで、全体の20.51%を占めています。2025Q4と比較して、機関の持ち株は-2119805.00増加しています。